| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-04-27 | A-Mansia (Belgium) | €13 million | series A financing round | Seventure (France) Fonds Vives II (Belgium) SRIW Life Sciences (Belgium) Nivelinvest (Belgium) Pierre Drion | Metabolic diseases | Series A financing round |
| 2018-04-26 | Mereo BioPharma (UK) | IPO | Rare diseases - Genetic diseases | IPO | ||
| 2018-04-19 | Tmunity Therapeutics (USA - PA) | $135 million | series A financing round | Kleiner Perkins (USA) Ping An Ventures (China) Parker Institute for Cancer Immunotherapy (USA - CA) Gilead Sciences, (USA - CA) Be The Match BioTherapies (USA - MN) University of Pennsylvania (USA - PA) Lilly Asia Ventures (China) | Cancer - Oncology | Series A financing round |
| 2018-04-02 | ITBMed (Sweden) | up to $67 million | financing round | Royalty Pharma (US - NY) | Transplantation | Financing round |
| 2018-03-27 | Poietis (France) | €5 million | series A financing round, grant | WiSEED (France) Nouvelle Aquitaine Coinvestment Fund (France) | Technology - Services | Series A financing round |
| 2018-02-23 | Fate Therapeutics (USA - CA) | $4 million | grant | California Institute for Regenerative Medicine (CIRM) (USA - CA) | Cancer - Oncology | Grant |
| 2018-02-23 | Fate Therapeutics (USA - CA) | $4 million | grant | California Institute for Regenerative Medicine (CIRM) (USA - CA) | Cancer - Oncology | Grant |
| 2018-02-16 | ABAC Therapeutics (Spain) | €16 million | series A financing round | Pontifax (Israel) Quark Venture (Canada) GF Securities (China) Caixa Capital Risc (Spain) Debiopharm Innovation Fund (Switzerland) Ferrer (Spain) | Infectious diseases | Series A financing round |
| 2018-02-07 | Sangamo Therapeutics (USA - CA) Case Western Research University (USA - OH) | $11 million | grant | National Institutes of Health (NIH) (USA) | Infectious diseases | Grant |
| 2018-02-05 | Metrion Biosciences (UK) | £200 000 | grant | Innovate UK Biomedical Catalyst Feasibility Award scheme (UK) | Autoimmune diseases - Neurodegenerative diseases | Grant |
| 2018-02-02 | Viking Therapeutics (USA - PA) | $55 million | private placement | Endocrinological diseases - Metabolic diseases | Private placement | |
| 2018-02-02 | Medivir (Sweden) | 155 million SEK (€ 15.75 million) | Infectious diseases | Private placement | ||
| 2018-02-01 | Avrobio (USA - MA) | $60 million | series B financing round | Cormorant Asset Management and Surveyor Capital (a Citadel company), and included participation by Aisling, Brace Pharma Capital, Eventide Asset Management and Morningside, along with existing investors Atlas Venture, SV Health Investors and Clarus Ventures. | Cancer - Oncology - Rare diseases - Genetic diseases | Series B financing round |
| 2018-01-29 | Audentes Therapeutics (USA - CA) | $231.4 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2018-01-23 | Tmunity Therapeutics (USA - PA) | $ 100 million | series A financing round | Ping An Ventures (China) Parker Institute for Cancer Immunotherapy (USA - CA) Gilead Sciences (USA - CA) Be The Match BioTherapies University of Pennsylvania (USA - PA) Lilly Asia Ventures (China) | Cancer - Oncology - Autoimmune diseases - Infectious diseases | Series A financing round |
| 2018-01-23 | Skyhawk Therapeutics (USA - MA) | $ 8 million | financing round | Tim Disney, the Duke of Bedford, Alexandria Venture Investments (USA - MA) and other undisclosed private investors | Cancer - Oncology - Neurological diseases | Financing round |
| 2018-01-23 | Ultragenyx Pharmaceutical (USA - CA) | $250 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2018-01-22 | Avexis (USA - IL) | $431.9 million | private placement | Rare diseases - Genetic diseases - Neuromuscular diseases | Private placement | |
| 2018-01-22 | Beigene (China) | $800 million | private placement | Cancer - Oncology | Private placement | |
| 2018-01-16 | Arbutus Biopharma (Canada) | US$116.4 million | private placement | Roivant Sciences (CH - USA) | Infectious diseases | Private placement |
